Mechanisms of the actions of aromatase inhibitors 4-hydroxyandrostenedione, fadrozole, and aminoglutethimide on aromatase in JEG-3 cell culture

Selective inhibition of estrogen production with aromatase inhibitors has been found to be an effective strategy for breast cancer treatment. Most studies have focused on inhibitor screening and in vitro kinetic analysis of aromatase inhibition using placental microsomes. In order to determine the effects of different inhibitors on aromatase in the whole cell, we have utilized the human choriocarcinoma cell line, JEG-3 in culture to compare and study three classes of aromatase inhibitors, 4-hydroxyandrostenedione, fadrozole (CGS 16949A), and aminoglutethimide. Fadrozole is the most potent competitive inhibitor and aminoglutethimide is the least potent among the three. However, stimulation of aromatase activity was found to occur when JEG-3 cells were preincubated with aminoglutethimide. In contrast, 4-OHA and fadrozole caused sustained inhibition of aromatase activity in both JEG-3 cells and placental microsomes, which was not reversed even after the removal of the inhibitors. 4-OHA bound irreversibly to the active site of aromatase and caused inactivation of the enzyme which followed pseudo-first order kinetics. However, 4-OHA appears to be metabolized rapidly in JEG-3 cells. Sustained inhibition of aromatase induced by fadrozole occurs by a different mechanism. Although fadrozole bound tightly to aromatase at a site distinct from the steroid binding site, the inhibition of aromatase activity by fadrozole does not involve a reactive process. None of the inhibitors stimulated aromatase mRNA synthesis in JEG-3 cells during 8 h treatment. The stimulation of aromatase activity by AG appeared to be due to stabilization of aromatase protein. According to these results, 4-OHA and fadrozole would be expected to be more beneficial in the treatment of breast cancer patients than AG. The increase in aromatase activity by AG may counteract its therapeutic effect and might be partially responsible for relapse of breast cancer patients from this treatment.

[1]  D. V. van Thiel,et al.  Clonal lines of human choriocarcinoma cells in culture. , 1971, Acta endocrinologica. Supplementum.

[2]  R. Hussa,et al.  Macromolecular synthesis is required for stimulation of estrogen synthetase activity by dibutyryl cyclic AMP plus theophylline in choriocarcinoma cell culture , 1981, Steroids.

[3]  W. Wouters,et al.  Aromatase in the human choriocarcinoma JEG-3: Inhibition by R 76 713 in cultured cells and in tumors grown in nude mice , 1991, The Journal of Steroid Biochemistry and Molecular Biology.

[4]  Leslie J. Browne,et al.  In vitro and in vivo studies demonstrating potent and selective estrogen inhibition with the nonsteroidal aromatase inhibitor CGS 16949A , 1987, Steroids.

[5]  I. Khan,et al.  Mechanism for control of hydroxymethylglutaryl-coenzyme A reductase and cytochrome P-450 side chain cleavage message and enzyme in the corpus luteum. , 1990, Endocrinology.

[6]  J. Kitawaki,et al.  Growth suppression of MCF-7 human breast cancer cells by aromatase inhibitors: A new system for aromatase inhibitor screening , 1993, The Journal of Steroid Biochemistry and Molecular Biology.

[7]  A. Brodie,et al.  The effect of an aromatase inhibitor, 4-hydroxy-4-androstene-3,17-dione, on estrogen-dependent processes in reproduction and breast cancer. , 1977, Endocrinology.

[8]  B. Metcalf,et al.  Time-dependent inhibition of aromatase in trophoblastic tumor cells in tissue culture. , 1984, Journal of steroid biochemistry.

[9]  D. Pompon,et al.  Structure-function studies of human aromatase by site-directed mutagenesis: kinetic properties of mutants Pro-308----Phe, Tyr-361----Phe, Tyr-361----Leu, and Phe-406----Arg. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[10]  P. Satoh,et al.  Aminoglutethimide (Elipten-Ciba) as an inhibitor of adrenal steroidogenesis: mechanism of action and therapeutic trial. , 1967, The Journal of clinical endocrinology and metabolism.

[11]  A. Brodie,et al.  Estrogen regulates vascular endothelial growth/permeability factor expression in 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors. , 1996, Endocrinology.

[12]  R. Brueggemeier,et al.  Aromatase inhibition by an enzyme-activated irreversible inhibitor in human carcinoma cell cultures. , 1990, Cancer research.

[13]  H. Brodie,et al.  Studies on the mechanism of estrogen biosynthesis. 8. The development of inhibitors of the enzyme system in human placenta. , 1973, Endocrinology.

[14]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[15]  D. Dabbs,et al.  Expression of aromatase protein and messenger ribonucleic acid in tumor epithelial cells and evidence of functional significance of locally produced estrogen in human breast cancers. , 1996, Endocrinology.

[16]  C. Mendelson,et al.  Isolation of a full-length cDNA insert encoding human aromatase system cytochrome P-450 and its expression in nonsteroidogenic cells. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[17]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[18]  M. Ascoli,et al.  Characterization of steroid production in cultured human choriocarcinoma cells. , 1981, The Journal of clinical endocrinology and metabolism.

[19]  W. Chan,et al.  Aminoglutethimide augments follicle-stimulating hormone-induced aromatase activity in cultured porcine granulosa cells. , 1988, Endocrinology.

[20]  S. Bates,et al.  Use of the polymerase chain reaction in the quantitation of mdr-1 gene expression. , 1990, Biochemistry.

[21]  Thompson Ea,et al.  The Involvement of Human Placental Microsomal Cytochrome P-450 in Aromatization , 1974 .

[22]  D. Covey,et al.  Aromatase enzyme catalysis is involved in the potent inhibition of estrogen biosynthesis caused by 4-acetoxy- and 4-hydroxy-4-androstene-3, 17-dione. , 1982, Molecular pharmacology.

[23]  M. Dowsett,et al.  Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients. , 1989, Cancer research.

[24]  Shiuan Chen,et al.  Kinetic properties of aromatase mutants Pro308Phe, Asp309Asn, and Asp309Ala and their interactions with aromatase inhibitors , 1992, The Journal of Steroid Biochemistry and Molecular Biology.

[25]  R. Koos,et al.  Expression of basic fibroblast growth factor in the rat ovary: detection of mRNA using reverse transcription-polymerase chain reaction amplification. , 1989, Molecular endocrinology.

[26]  R. Hussa,et al.  Estrogen synthetase in choriocarcinoma cell culture. stimulation by dibutyryl cyclic adenosine monophosphate and theophylline , 1978, Steroids.

[27]  C. Tsai-Morris,et al.  Inactivation of aromatase in vitro by 4-hydroxy-4-androstene-3,17-dione and 4-acetoxy-4-androstene-3,17-dione and sustained effects in vivo , 1981, Steroids.

[28]  G. Farrell,et al.  Induction of cytochrome P450 2B1 in rat liver by the aromatase inhibitor aminoglutethimide. , 1993, The Journal of pharmacology and experimental therapeutics.

[29]  M. Dowsett,et al.  Endocrine changes associated with relapse in advanced breast cancer patients on aminoglutethimide therapy. , 1984, The Journal of clinical endocrinology and metabolism.